within Pharmacolibrary.Drugs.ATC.A;

model A05AX06
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.00023666666666666665,
    adminDuration  = 600,
    adminMass      = 120 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.118,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.011333333333333334,
    Tlag           = 15.0,            
    Vdp             = 0.405,
    k12             = 36.4,
    k21             = 36.4
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A05AX06</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Elafibranor is a dual peroxisome proliferator-activated receptor (PPAR) alpha/delta agonist developed for the treatment of metabolic diseases, chiefly nonalcoholic steatohepatitis (NASH). It has been investigated in clinical trials but is not approved for clinical use as of 2024.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects after oral administration.</p><h4>References</h4><ol><li><p>Goyal, NP, et al., &amp; Schwimmer, JB (2023). An Open Label, Randomized, Multicenter Study of Elafibranor in Children With Nonalcoholic Steatohepatitis. <i>Journal of pediatric gastroenterology and nutrition</i> 77(2) 160–165. DOI:<a href=\"https://doi.org/10.1097/MPG.0000000000003796\">10.1097/MPG.0000000000003796</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37084342/\">https://pubmed.ncbi.nlm.nih.gov/37084342</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A05AX06;
